Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Terlipressin or Europressin? | Available online http ccforum.eom content 13 5 192 Commentary Terlipressin or Europressin Marc Leone Service d anesthesie et de réanimation Hôpital Nord Chemin des Bourrely 13915 Marseille cedex 20 France Corresponding author Marc Leone marc.leone@ap-hm.fr Published 7 October 2009 This article is online at http ccforum.com content 13 5 192 2009 BioMed Central Ltd Critical Care 2009 13 192 doi 10.1186 cc8035 See related research by Morelli et al. http ccforum.com content 13 4 R130 Abstract Use of terlipressin in septic shock relies on a series of European studies resulting in a better knowledge of this vasopressive agent. Additional studies demonstrate that this agent appears to have attractive properties when administered properly. In comparison to prior reports continuous infusion of low-dose terlipressin seems superior when administered to septic animals. For the first time in humans Morelli and colleagues compared this mode of administration with other vasopressors. In the previous issue of Critical Care a European group made a new contribution to the terlipressin literature 1 . For the first time terlipressin vasopressin and norepinephrine were compared among patients with septic shock. Because vasopressin is not available in most European countries terlipressin a vasopressin analog was used in patients with norepinephrine-resistant septic shock. Terlipressin is initially indicated in patients with hepatorenal syndrome and bleeding esophageal varices. In 2001 a German group showed its efficacy in endotoxemic sheep 2 . In 2002 a British group treated eight patients with norepinephrine-resistant septic shock by repeated bolus administration of terlipressin 3 . In 2004 studies from France Spain and Italy confirmed the feasibility of terlipressin in septic shock 4-6 . Vasopressin and its analogs act on three subtypes of receptors V1 V2 and V3 7 . V1 receptors are found on various cells including vascular smooth muscle cells causing vasoconstriction. V2 receptors .
